Intervention1: Bepirovirsen: 150 mg/mL
Sponsors
GSK Research & Development Limited
Conditions
Health Condition 1: D50-D89- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
Phase 3
Study is intended to confirm fficacy, safety, PK profile & the durability of HBsAg suppression observed with bepirovirsen 300 mg weekly for 24 weeks (with loading doses) as compared to the placebo arm
Active, not recruitingCTRI/2023/02/050042
Target: 534Updated: 2026-06-01
This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and the durability of hepatitis B virus surface antigen (HBsAg) suppression observed with bepirovirsen for 24 weeks (with loading doses) as compared to the placebo arm.
Active, not recruitingCTRI/2023/02/050043
Target: 534Updated: 2026-06-01